PharmaEngine, Inc. (TPEX:4162)

Market Cap	7.70B -38.9%
Revenue (ttm)	963.83M -62.1%
Net Income	422.55M -76.1%
EPS	2.94 -76.1%
Shares Out	143.68M
PE Ratio	18.24
Forward PE	19.42
Dividend	2.00 (3.73%)
Ex-Dividend Date	Aug 13, 2025

Volume	586,839
Open	53.50
Previous Close	53.00
Day's Range	53.10 - 53.80
52-Week Range	53.00 - 91.90
Beta	0.17
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2026

About PharmaEngine

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is also developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 45
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4162

Financial Performance

In 2025, PharmaEngine's revenue was 911.42 million, a decrease of -63.88% compared to the previous year's 2.52 billion. Earnings were 387.64 million, a decrease of -77.86%.